智通财经APP获悉，中共中央政治局常委、国务院总理李强8月20日在北京调研生物医药产业发展情 况。他强调，要深入贯彻习近平总书记关于生物医药产业发展的重要指示精神，加大高质量科技供给和 政策支持，充分发挥企业创新主体作用，着力推动生物医药产业提质升级，研发生产更多优质高效的好 药新药，不断增进人民健康福祉。相关概念股：基石药业-B(02616)、和誉-B(02256)、和铂医药 (02142)、信达生物(01801)。 调研中，李强主持召开座谈会。听取有关企业和投资、研发、医疗机构负责人发言后，李强指出，生物 医药产业既是战略性新兴产业，也事关人民健康福祉。要加强原始创新和关键核心技术攻关，发挥政府 和市场两方面作用，充分调动各类资源，凝聚创新合力，尽快取得更大突破。要注重运用人工智能全面 赋能产业发展，提高药物研发、临床试验、诊断治疗、生产流通等环节智能化水平。要强化产品研发、 审评审批、管理使用等政策衔接和协同配合，优化药品集采和谈判议价机制，加大高水平创新药应用指 导力度。李强强调，要依靠创新促进中医药振兴发展，充分运用现代科学的理论、技术、材料等，深化 中医药基础理论、诊疗规律、作用机理的研究阐释，丰 ...

Core Insights - The Chinese government emphasizes the importance of strengthening pharmaceutical innovation and research to support public health and the development of innovative drugs and medical devices [1] - The trend of Chinese innovative drugs going global is gaining momentum, with significant increases in business development (BD) transactions and funding [2][3] - The pharmaceutical sector is expected to recover in 2025, driven by high-value BD transactions and an improving policy environment [3][4] Industry Developments - The Chinese innovative drug market is projected to see a surge in international collaborations, with over 80 BD projects completed by 2025, indicating a growing global competitiveness [2] - In Q1 2025 alone, BD transactions reached 41, with a total value of approximately 369.29 billion USD, nearing the total for the previous year [2] - Major transactions include the licensing of PD-1/VEGF dual antibody SSGJ-707 to Pfizer for 60.5 billion USD and the global rights for Tislelizumab to Vor Bio for up to 42.3 billion USD [2] Company Highlights - Companies like 基石药业-B (02616) showcased innovative products at the AACR annual meeting, highlighting their advancements in clinical research [5] - 和誉-B (02256) received priority review for its CSF-1R inhibitor for treating TGCT, indicating regulatory support for innovative therapies [6] - 和铂医药 (02142) entered a significant strategic partnership with AstraZeneca, securing 1.75 billion USD in upfront payments and potential milestone payments totaling up to 44 billion USD [6] - 信达生物 (01801) aims to achieve 20 billion RMB in product sales by 2027, with multiple catalysts expected in the coming years, including potential drug launches and data readouts [7]

Group 1: Hong Kong Monetary Environment - The President of the Hong Kong Monetary Authority, Yu Weiwen, stated that the current low interest rate environment for the Hong Kong dollar may not be sustainable, and citizens should consider potential risks when making property, investment, or borrowing decisions [1] - The supply of Hong Kong dollar funds has become abundant due to a significant increase in surplus, but future fluctuations in the Hong Kong dollar exchange rate and interest rates remain uncertain [1] Group 2: Financial Data and Tax Revenue - From January to April, the national general public budget revenue was 80,616 billion yuan, a year-on-year decrease of 0.4%, with tax revenue at 65,556 billion yuan, down 2.1% [3] - The securities transaction stamp duty reached 53.5 billion yuan, marking a year-on-year increase of 57.8% [3] Group 3: Company Developments - Xinhua Insurance is set to participate in the third batch of insurance fund long-term investment reform pilot projects, aiming to increase its allocation to Hong Kong stocks [3] - Zhaoyi Innovation plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders and market conditions [4] - CNOOC Defense expects the current shipbuilding market cycle to continue, supported by a balanced global shipyard capacity and demand for fleet renewal [5] - GCL-Poly Energy's assistant vice president indicated that the cost of granular silicon still has room for reduction, with inventory levels remaining low [5] - Nongfu Spring's chairman stated that while the company does not oppose outsourcing, all current products cannot be outsourced due to high dependency on water sources and customized production systems [6] - Hisense Visual released the industry's first "projection-level" home theater equipment, featuring advanced laser projection technology [7] - Huyou-B's CSF-1R inhibitor has been prioritized for review by the National Medical Products Administration for treating TGCT [8] - Shanghai Pharmaceuticals received FDA approval for its rivaroxaban tablets [9] - Tencent launched the first industrial-grade AIGC game content production engine, significantly enhancing game asset generation efficiency [10] Group 4: Financial Performance - ZTO Express reported a 40.9% year-on-year increase in net profit for Q1, reaching 2.0392 billion yuan, with a 19.1% increase in package volume [10] - Gome Retail achieved a profit of 405 million yuan, turning around from a loss, despite a 1.4% decrease in revenue [10] - Huazhu Group's Q1 net profit increased by 35.66% to 894 million yuan, with total revenue rising by 2.22% [11] - Bilibili reported a 24% increase in total revenue for Q1, reaching 7.003 billion yuan, with an adjusted net profit of 362 million yuan, marking a return to profitability [12]

Group 1 - On May 20, 2023, 3SBio announced a licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody "SSGJ-707," granting Pfizer exclusive global rights outside mainland China, with a potential total deal value of $60.5 billion, exceeding 430 billion RMB at current exchange rates [1] - The agreement includes a non-refundable upfront payment of $1.25 billion and up to $4.8 billion in milestone payments for development, regulatory approval, and sales, along with a tiered sales royalty based on product sales in licensed regions [1] - Following the announcement, 3SBio's stock surged over 32%, reaching a market capitalization of 46 billion HKD [1] Group 2 - 3SBio's CEO stated that Pfizer's extensive development experience and international perspective will significantly accelerate the global development and commercialization of SSGJ-707, aiming to provide breakthrough treatment options for patients worldwide [2] - The trend of Chinese innovative drugs entering international markets is expanding, with recent agreements such as CSPC's exclusive licensing deal with Cipla for irinotecan liposome injection in the U.S., which includes a $15 million upfront payment and potential total payments nearing $1.1 billion [2] - Data from Yaozhi shows that in 2024, there were 94 completed outbound licensing transactions for Chinese innovative drugs, totaling $51.9 billion, a 26% year-on-year increase, with 41 transactions in the first quarter of 2025 alone, amounting to $36.9 billion, setting new historical highs [2] Group 3 - On May 12, 2023, former President Trump signed an executive order aimed at reducing prescription drug prices in the U.S., suggesting that prices should decrease by at least 59%, with potential reductions of 80% or 90% in certain cases [3] - Guoyuan Securities believes that the push for drug price reductions in the U.S. will not significantly impact the outbound licensing of innovative drugs from China, citing factors such as low prices for generics and intense competition in the U.S. market [3] - The firm anticipates that the pharmaceutical industry will enter a performance vacuum period starting in May, shifting market focus from earnings to fundamental changes in the industry and companies, maintaining a positive outlook on innovative drugs and international expansion [3] Group 4 - Related concept stocks include Cornerstone Pharmaceuticals, which showcased five innovative products at the AACR annual meeting, including a tri-specific antibody and several ADC molecules [4] - Hanyu Pharmaceuticals announced that its selective small molecule CSF-1R inhibitor has been prioritized for review by the Chinese National Medical Products Administration for treating TGCT patients [4] Group 5 - Hengrui Medicine entered a significant strategic collaboration with AstraZeneca, which includes licensing options for two preclinical immunotherapy projects, with Hengrui receiving $175 million in upfront and milestone payments, plus potential royalties based on net sales [5]